Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics


Dr. Reddy's Laboratories Ltd (RDY)

Today's Latest Price: $47.25 USD

2.66 (5.97%)

Updated Apr 8 1:15pm

Add RDY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RDY Stock Summary

  • The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than only 2.83% of stocks in our set with a positive cash flow.
  • In terms of volatility of its share price, RDY is more volatile than merely 4.33% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDY comes in at 311.01% -- higher than that of 98.18% of stocks in our set.
  • Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are WBC, BRKR, GENC, NSSC, and MOG.A.
  • RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.
RDY Daily Price Range
RDY 52-Week Price Range

RDY Stock Price Chart More Charts


RDY Price/Volume Stats

Current price $47.25 52-week high $47.43
Prev. close $44.59 52-week low $33.33
Day low $45.51 Volume 461,011
Day high $47.43 Avg. volume 217,821
50-day MA $41.77 Dividend yield 0.58%
200-day MA $39.48 Market Cap 7.83B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio


Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$47.25$2119.454653%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 93th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:

  • The company has produced more trailing twelve month cash flow than 99.03% of its sector Healthcare.
  • The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than merely 16.45% of the free cash flow producing stocks we're observing.
  • RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 51.31% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%4560%
1%4607%
2%4653%
3%4700%
4%4746%
5%4793%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RDY, try USNU, HZNP, THC, SUPN, and BEAT.


RDY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

RDY Latest Social Stream


Loading social stream, please wait...

View Full RDY Social Stream

RDY Price Returns

1-mo 17.83%
3-mo 14.57%
6-mo 26.54%
1-year 18.67%
3-year 17.56%
5-year -19.22%
YTD 16.44%
2019 8.38%
2018 1.18%
2017 -16.47%
2016 -1.67%
2015 -7.76%

RDY Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7761 seconds.